Streetbeat News

Stock Prices

VIOT

Viomi Technology has announced an extension of its share repurchase plan for an additional 12 months, demonstrating its commitment to enhancing shareholder value.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 10:12 am

RVMD

Revolution Medicines reported positive results for its RAS(ON) multi-selective inhibitor, RMC-6236, showing encouraging antitumor activity and safety in patients with previously treated pancreatic ductal adenocarcinoma (PDAC).

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 10:10 am

CSTM

Constellium is facing macroeconomic and geopolitical uncertainties, leading to a cautious outlook for 2025. The company expects its 2024 Adjusted EBITDA to be between €580 million and €600 million, excluding certain impacts.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 10:09 am

SDGR

Schrödinger presented new preclinical data on its investigational Wee1/myt1 inhibitor, SGR-3515, at the 36th EORTC-NCI-AACR Symposium. This development could impact the company's research and development prospects.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 10:09 am

RPTX

Repare Therapeutics presented updated data from its Phase 1 MYTHIC trial, showing that an individualized treatment schedule for Lunresertib and Camonsertib effectively manages anemia while maintaining clinical benefits. The new schedule reduced Grade 3 anemia and other adverse events.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 10:07 am

HLT

Hilton Worldwide has released its Q4 2024 financial outlook, projecting adjusted EPS between $1.57 and $1.67, below the $1.77 estimate. GAAP EPS is expected to be between $1.49 and $1.59, also below the $1.65 estimate. System-wide RevPAR is projected to increase by 1.0% to 2.0% compared to Q4 2023.

Portfolio Pulse from Mohit Manghnani

October 23, 2024 | 10:05 am

HLT

Hilton Worldwide has lowered its FY24 GAAP EPS outlook to $5.58-$5.68 from a previous range of $6.06-$6.15, which is below the $6.15 estimate. The company projects a 2.0-2.5% increase in RevPAR, adjusted EPS of $6.93-$7.03, and net income of $1,405-$1,429 million.

Portfolio Pulse from Mohit Manghnani

October 23, 2024 | 10:04 am

VRT

Vertiv Holdings has raised its outlook for FY24 adjusted EPS to a range of $2.66 - $2.70, up from the previous range of $2.47 - $2.53, surpassing the estimated $2.49.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 10:03 am

TMO

Thermo Fisher Scientific has raised its 2024 adjusted EPS guidance to a range of $21.35-$22.07, slightly above its previous guidance and the consensus estimate.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 10:03 am

HLT

Hilton Worldwide has reiterated its FY24 adjusted EPS outlook of $6.93-$7.03, slightly below the $7.06 estimate. The company projects a 2.0-2.5% increase in RevPAR, net income between $1,405M and $1,429M, and adjusted EBITDA between $3,375M and $3,405M. Capital return is expected to be around $3.0 billion.

Portfolio Pulse from Mohit Manghnani

October 23, 2024 | 10:03 am